Spirit Magazine - April 2014 - (Page 26)

certain beauty in his behavior. Maybe it's because I saw myself in him. My life's obsession is the harp. It propels me out of bed each morning. I played full time for more than 20 years. About 15 years ago, an injury forced me to stop. Although devastated by this turn of events, I was introduced to new ways of sharing my love for the instrument. I became Important Information for Patients about PATADAY® (olopatadine hydrochloride ophthalmic solution) 0.2% This summary contains risk and safety information for patients about PATADAY® Solution. This summary does not include all information about PATADAY® Solution and is not meant to take the place of talking to your healthcare provider about your medical condition or treatment. Please see the full Prescribing Information for complete product information available at www.Pataday.com. Read the Prescribing Information that comes with PATADAY® Solution before you start using it and each time you get a refill. There may be new information. If you have questions about PATADAY® Solution, talk to your doctor or pharmacist. INDICATIONS AND USAGE PATADAY® Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. DOSAGE AND ADMINISTRATION The recommended dose is one drop in each affected eye once a day. DOSAGE FORMS AND STRENGTHS Ophthalmic solution 0.2%: each ml contains 2.22 mg of olopatadine hydrochloride. CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS For topical ocular use only. Not for injection or oral use. Contamination of Tip and Solution As with any eye drop, to prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. Contact Lens Use Patients should be advised not to wear a contact lens if their eye is red. PATADAY® (olopatadine hydrochloride ophthalmic solution) 0.2% should not be used to treat contact lens related irritation. The preservative in PATADAY® Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red, should be instructed to wait at least ten minutes after instilling PATADAY® (olopatadine hydrochloride ophthalmic solution) 0.2% before they insert their contact lenses. ADVERSE REACTIONS Symptoms similar to cold syndrome and pharyngitis were reported at an incidence of approximately 10%. The following adverse experiences have been reported in 5% or less of patients: Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus. Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion. Some of these events were similar to the underlying disease being studied. a private instructor and opened one of the few harp stores in America-Harps Etc.-in Walnut Creek, California. My obsession helped guide me to a new life. So, you see, sometimes an obsession is a good thing. -J E S S I C A S I EG E L WA L N U T C R E E K , C A L I FO R N I A A good thing, indeed. Talk about striking a chord, Jessica. USE IN SPECIFIC POPULATIONS Pregnancy Teratogenic effects: Pregnancy Category C Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 150,000 times the maximum recommended ocular human dose (MROHD) and rabbits treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during organogenesis showed a decrease in live fetuses. In addition, rats treated with 600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal weight. Further, rats treated with 600 mg/kg/day of olopatadine during late gestation through the lactation period showed a decrease in neonatal survival and body weight. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. Nursing Mothers Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when PATADAY® (olopatadine hydrochloride ophthalmic solution) 0.2% is administered to a nursing mother. Pediatric Use Safety and effectiveness in pediatric patients below the age of 2 years have not been established. Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients. NONCLINICAL TOXICOLOGY Carcinogenesis, Mutagenesis, Impairment of Fertility Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 μL drop size and a 50 kg person, these doses were approximately 150,000 and 50,000 times higher than the MROHD. No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of approximately 100,000 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of approximately 15,000 times the MROHD level. OPERATION COOKIE Our love for Southwest (and Spirit magazine) was proclaimed loudly this holiday season. For years, we have sent cookies as gifts. The inspiration for this year's gifts was discovered while on a flight to a friend's wedding. We used six recipes from your September 2013 cookie issue, with overwhelming success. Total cookies baked: 1,018. Total boxes sent: 42. Total states represented: 12. The response was extremely positive. Thank you for entertaining us, in flight and on the ground. -LORI & TORREY BIEVENOUR INDIANAPOLIS Sweet! One question: Can we get on the list for next year? UNCLE WALLY This is a very belated note to tell you how much I enjoyed your profile of Wally Amos ["Are You Famous Amos?," September 2013]. I got hooked on Uncle Noname cookies at one point in my life- they were always in the vending machine, and I was always working late-and I remember the packaging making reference to Wally not being able to use his famous name. I always wondered about the backstory and what became of him. Your story gave me this information and so much more. I really enjoyed learning about his life, both the highs and the lows, and I appreciate that you neither glorified nor demonized him. After reading your story, I feel like I know the man, yet I also understand what his kids went through and how they perceive him now. - D AV E K L I N E S A C R A M E N T O, C A L I FO R N I A  We're glad you liked the story, Dave. Rx only Reference: 1. IMS Health, IMS National Prescription Audit, August 2010 to October 2013, USC 61500 OPHTH ANTI-ALLERGY. ‡ This information is an estimate derived from the use of information under license from the following IMS Health information service: National Prescription Audit for the period 2004-2013. IMS expressly reserves all rights, including rights of copying, distribution and republication. © 2014 Novartis 1/14 PAT14001JAD CORRECTION The March Rapid Rewards Freedom Story reported that Taylor Hicks will perform at Caesars Palace. The actual venue is Paris Las Vegas. We regret this error. http://www.Pataday.com http://www.Pataday.com

Table of Contents for the Digital Edition of Spirit Magazine - April 2014

Spirit Magazine - April 2014
Contents
Gary’s Greeting
Gary’s Greeting en Español
Star of the Month
Freedom Story
From the Editor
Your Words
Your Pictures
Media Center
Eat Drink Sleep
Rustle up ribs
shake up a summer sipper
Wise Guide
Take better snaps
Make finance a family affair
Numbers
Make time for sweets
Learn from the Bard
Business
Zen out with Russell Simmons
Store more on your iPhone
Chasing Beautiful Questions
Connection Error
Get out of your social comfort zone
Your Adventure In Santa Fe
Destination Texas
Calendar
Fun!
Spotlight
Community Outreach
Products & Services
Flight Service
Terminal Maps
Information
Rapid Rewards and A+ Rewards Partners
Route Map
The "If" List
Touch base with Tracy Morgan

Spirit Magazine - April 2014

https://www.nxtbook.com/nxtbooks/pace/southwest_201412
https://www.nxtbook.com/nxtbooks/pace/southwest_201411
https://www.nxtbook.com/nxtbooks/pace/southwest_201410
https://www.nxtbook.com/nxtbooks/pace/southwest_201409
https://www.nxtbook.com/nxtbooks/pace/spirit_201408
https://www.nxtbook.com/nxtbooks/pace/spirit_201407
https://www.nxtbook.com/nxtbooks/pace/spirit_201406
https://www.nxtbook.com/nxtbooks/pace/spirit_201405
https://www.nxtbook.com/nxtbooks/pace/spirit_201404
https://www.nxtbook.com/nxtbooks/pace/spirit_201403
https://www.nxtbook.com/nxtbooks/pace/spirit_201402
https://www.nxtbook.com/nxtbooks/pace/spirit_201401
https://www.nxtbook.com/nxtbooks/pace/spirit_201312
https://www.nxtbook.com/nxtbooks/pace/spirit_201311
https://www.nxtbook.com/nxtbooks/pace/spirit_201310
https://www.nxtbook.com/nxtbooks/pace/spirit_201309
https://www.nxtbook.com/nxtbooks/pace/spirit_201308
https://www.nxtbook.com/nxtbooks/pace/spirit_201307
https://www.nxtbook.com/nxtbooks/pace/spirit_201306
https://www.nxtbook.com/nxtbooks/pace/spirit_201305
https://www.nxtbook.com/nxtbooks/pace/spirit_201304
https://www.nxtbookmedia.com